The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval
| العنوان: | The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval |
|---|---|
| المؤلفون: | Andrei Iagaru, Guido Davidzon, Ryusuke Nakamoto, Judy Nguyen, Kip Guja, Farshad Moradi, Carina Mari Aparici, Hong Song, Benjamin L. Franc, Caitlyn Harrison, Negin Hatami |
| المصدر: | Molecular Imaging and Biology. 23:614-623 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Biochemical recurrence, Cancer Research, PET-CT, Prostatectomy, business.industry, medicine.medical_treatment, Fda approval, medicine.disease, 030218 nuclear medicine & medical imaging, Radiation therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Oncology, Cohort, medicine, Radiology, Nuclear Medicine and imaging, Recurrent prostate cancer, business, Nuclear medicine |
| الوصف: | To evaluate the diagnostic performance and clinical utility of 18F-fluciclovine PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC). 18F-Fluciclovine scans of 165 consecutive men with BCR after primary definitive treatment with prostatectomy (n = 102) or radiotherapy (n = 63) were retrospectively evaluated. Seventy patients had concurrent imaging with at least one other conventional modality (CT (n = 31), MRI (n = 31), or bone scan (n = 26)). Findings from 18F-fluciclovine PET were compared with those from conventional imaging modalities. The positivity rate and impact of 18F-fluciclovine PET on patient management were recorded. In 33 patients who underwent at least one other PET imaging (18F-NaF PET/CT (n = 12), 68Ga-PSMA11 PET/CT (n = 5), 18F-DCFPyL PET/CT (n = 20), and 68Ga-RM2 PET/MRI (n = 5)), additional findings were evaluated. The overall positivity rate of 18F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA |
| تدمد: | 1860-2002 1536-1632 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::dfbc2e52a21682f4ce80b42f2180012d https://doi.org/10.1007/s11307-021-01583-3 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........dfbc2e52a21682f4ce80b42f2180012d |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 18602002 15361632 |
|---|